Thiospa

Quick links to important sections

Thiospa

Method of action: Muscle Relaxant

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thiospa

What is Thiospa? Thiocolchicoside

This section provides a factual overview of Thiospa, defining its identity, type, and general therapeutic function.


Quick Facts: Thiocolchicoside Overview

Property Description
Active ingredient Thiocolchicoside
Form Tablet, capsule, intramuscular (IM) injection solution, topical gel
Pharmacological class Skeletal Muscle Relaxant ATC M03BX05
Common use Relieving painful muscle contractures and spasms
Origin Semi-synthetic derivative of colchicine

What Type of Medicine is Thiospa? (Definition and Classification)

Thiospa is a medicinal product whose active component, Thiocolchicoside, is clinically recognized as a centrally acting skeletal muscle relaxant, a category of drugs that primarily works through the central nervous system to ease muscle tension. The substance is a semi-synthetic glucoside derivative produced from colchicine, a compound naturally sourced from the Colchicum autumnale plant. This classification confirms its function of modulating nerve signals rather than acting directly on muscle fibers.

Composition and Available Forms

Thiocolchicoside is available either as a single-ingredient product or, frequently, as a fixed-dose combination product alongside a non-steroidal anti-inflammatory drug (NSAID). This approach allows for a combined therapeutic effect, addressing both the muscle rigidity and associated inflammatory pain. The medicine is manufactured in several pharmaceutical preparations, including oral forms such as the tablet or capsule, a solution for intramuscular (IM) injection, and a topical gel.

General Purpose and Core Benefit

The main purpose of Thiocolchicoside is to provide effective myorelaxant activity by addressing the involuntary muscle spasms and hypertonia that restrict movement. Its central muscle-easing action helps to release the painful muscle contractures that accompany acute musculoskeletal stiffness, resulting in symptomatic relief and the potential restoration of functional mobility. This demonstrates its primary benefit is the reduction of muscle tightening and associated discomfort.

What side effects are possible with Thiospa?

Possible Side Effects and Safety Information

The primary safety concern documented by regulatory bodies for Thiospa (Thiocolchicoside) relates to the aneugenic potential of its metabolite, M2. Aneuploidy (an abnormal number of chromosomes) is an established risk factor for severe adverse outcomes, including teratogenicity (birth defects), embryo/foeto-toxicity, spontaneous abortion, and impaired male fertility. It is also considered a theoretical risk factor for cancer, especially with long-term exposure.

Commonly Reported Adverse Reactions

The most frequently reported adverse reactions generally involve the gastrointestinal and nervous systems. These common effects include:

  • Drowsiness or Sleepiness
  • Diarrhea
  • Nausea and Vomiting
  • Dizziness

Regulatory Safety Restrictions and Contraindications

Due to the risks associated with the M2 metabolite, the use of Thiocolchicoside is subject to strict regulatory measures and is formally contraindicated in the following populations:

  • Pregnant women and women of childbearing potential who are not using effective contraception.
  • Breastfeeding women.
  • Children and adolescents under 16 years of age.

The medication is restricted to short-term use only at prescribed maximum daily doses (e.g., typically no more than 7 consecutive days for oral forms) to minimize exposure to the metabolite M2. Use at doses exceeding the recommended limits or for long-term treatment of chronic conditions must be avoided. Caution is also advised in patients with epilepsy or a history of seizure risk, as the medication may predispose to convulsions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Thiocolchicoside (Thiospa) strictly defines the manifestations of overdose and the required emergency actions.


Documented Manifestations and Actions

Classification Official Regulatory Statement
Documented Manifestations Overdosage may present with digestive signs, including diarrhoea or vomiting. Severe outcomes include the potential for seizures or the acceleration of seizures in susceptible patients.
Antidote Information No specific antidote is known for Thiocolchicoside.
Required Management Treatment is solely symptomatic and supportive.
Monitoring Monitoring by a physician is a required component of management.

When to Seek Urgent Medical Attention

In the event of suspected overdosage, the official regulatory guidance requires that patients seek immediate medical attention. This instruction is mandatory because management involves clinical supervision and supportive measures that cannot be performed outside of a medical setting. The primary concern is addressing symptoms and ensuring patient safety until the effects of the compound are mitigated.

Population Considerations

The official overdose section of the prescribing information does not document specific differential management or symptom profiles tailored to pediatric, elderly, or renally/hepatically impaired populations.

Therapeutic Uses of Thiospa

Thiocolchicoside is applied in clinical settings for symptomatic support in conditions where muscle tension and rigidity create noticeable physiological strain.

The medication is commonly used to help with symptoms of increased muscular activity and is relevant for managing symptom clusters that may become intense or disruptive. This generally includes symptom clusters related to inflammatory or irritative states, such as painful, involuntary muscle contractures and muscle spasms associated with acute spinal pathology.

“This application provides support that helps ease the overall symptom burden when muscle rigidity interferes with daily comfort.”

Quick Fact: Symptomatic Support

Feature Description
Primary Symptoms Painful muscle contractures, involuntary spasms, muscular rigidity.
Main Indication Context Conditions characterized by periods of heightened symptoms, such as acute spinal discomfort.
Patient Benefit Supports easing distress and assists with maintaining functional stability.

Thiocolchicoside is generally applied in clinical settings that involve acute or unstable symptom patterns, such as phases following trauma or sudden flare-ups. It is relevant in contexts involving heightened systemic burden and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

The eligibility profile for systemic Thiospa (Thiocolchicoside) is heavily restricted by official regulatory decisions, primarily by the European Medicines Agency (EMA).

Contraindicated Populations (Must Not Use) Regulatory Status Affected Population
Contraindicated Women who are pregnant or breastfeeding (lactating).
Contraindicated Women of childbearing potential who are not using effective contraception.
Contraindicated Children and adolescents under 16 years of age.
Contraindicated Patients with hypersensitivity to the active substance or excipients.

Age-Group and Condition Rules

The medicine is officially recommended only for adults and adolescents from 16 years of age onwards. Use is not recommended for the longer-term treatment of chronic conditions; doses must be limited to the maximum recommended short-term duration.

Furthermore, the medicine must be administered with caution to patients with a history of epilepsy or those at risk of convulsions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Thiocolchicoside (Thiospa) based primarily on pharmacodynamic effects and specific risks associated with co-administration, rather than common metabolic interactions.


Pharmacodynamic and Additive Effects

Co-administration with other skeletal muscle relaxants is not recommended by regulatory authorities. This restriction is based on the potential for an increased effect of the muscle-easing properties, which constitutes an additive pharmacodynamic interaction.

Caution is formally required when Thiocolchicoside is used alongside medicines that produce effects on smooth muscles. Regulatory warnings state this combination may lead to a higher incidence rate of side effects.


Specific Co-administration Risks

Concomitant Substance Class Official Regulatory Outcome/Restriction
Skeletal Muscle Relaxants Co-administration is not recommended due to risk of increased effect.
Medicines affecting Smooth Muscles Caution required due to possible increase in side effect incidence.
NSAIDs or Paracetamol (Acetaminophen) Associated in post-marketing reports with serious cases of cytolytic or cholestatic hepatitis when co-administered.

Official regulatory labeling currently does not feature documented pharmacokinetic interactions, such as those mediated by Cytochrome P450 enzymes or drug transporters. Therefore, label-based restrictions concerning metabolic or clearance constraints with other medicinal products are absent.

Mechanism of Action

How Thiospa Works: Mechanism of Action

The mechanism involves activity in the spinal cord and brainstem, where its active metabolite functions as an agonist on key inhibitory sites, primarily glycine receptors and specific subtypes of GABA A receptors. The potentiation of these natural inhibitory signals dampens the excessive firing of motor neurons, resulting in the physiological reduction of muscle hypertonia.

Dual Pathway Modulation

The molecular profile exhibits two complementary actions: central inhibition and a separate molecular effect involving the inhibition of the NF-kappa B pathway. This transcription factor regulates the cellular production of pro-inflammatory mediators. This dual pathway modulation results in central skeletal muscle relaxation and the suppression of molecular inflammation.

While the primary action is central inhibition, the molecule's interaction with the GABA A system includes antagonistic or modulatory actions on other subtypes. This off-target modulation defines a mechanistic constraint by influencing the brain's overall excitability, which is a functional consequence of the molecule's structure.

Dosage and Administration Information

How to Use Thiospa: Official Administration Guidelines

This map outlines the standardized procedural instructions for the use of Thiocolchicoside (Thiospa).


Administration Scope

Category Instruction
Route of administration Approved for Oral (tablets/capsules), Intramuscular (IM) injection, and Topical (gel/cream) administration.
Dosing schedule (maximal daily dose) Oral systemic use: 16 mg per day; IM systemic use: 8 mg per day.
Timing in relation to meals Oral forms should be swallowed whole with a glass of water and may be taken with or after food.
Preparation requirements IM injection solution must be administered only via the intramuscular route by a qualified healthcare professional.
Age-group administration rules Systemic use (Oral/IM) is approved for adults and adolescents aged 16 years and older. Not for use in children under 16 years of age.
Missed-dose rules Standard procedure is to take the next dose at the regularly scheduled time; the missed dose is not taken.
Special procedural conditions The total duration of treatment must not exceed 7 consecutive days for oral use and 5 consecutive days for IM injection.

Instruction Classifications (High-Level)

Category Instruction
Administration method type Systemic (Oral, IM) and Local (Topical).
Frequency pattern Twice daily (b.i.d.) for systemic administration (every 12 hours).
Standardization Governed by established clinical guidelines and health standards.
Use-context constraints Restricted exclusively to short-term administration, defined by explicit time limits.

Resulting Procedural Structure

Official step sequence (Systemic Use):

  • The selected systemic form (Oral or IM) is administered at a dose of 8 mg (Oral) or 4 mg (IM) at the start of the daily cycle.
  • The dose is repeated 12 hours later, reaching the maximal daily limit (16 mg Oral or 8 mg IM).
  • This twice-daily dosing pattern is followed for a maximum of 7 consecutive days (Oral) or 5 consecutive days (IM).

Connection to the overall use protocol: The official instructions establish a precise, strictly time-bound protocol that governs all aspects of systemic Thiocolchicoside use. This procedural structure defines the maximum permitted daily dose and mandates that the medicine is administered in a twice-daily frequency only within the defined short-term duration limits for patients 16 years and older.

Recent Clinical Evidence

Research evidence / Overview of Studies for Thiospa

Evidence for Use in Painful Muscle Contractures in Acute Spinal Pathology (Systemic Use)

Research has primarily studied the oral and injectable forms of Thiocolchicoside in short-term Randomized Controlled Trials (RCTs). These studies were conducted on adult patients experiencing acute, often temporary, episodes of conditions associated with muscle spasms. Researchers examined how short-term use was associated with differences in outcomes related to physical discomfort (like pain scores) and outcomes reflecting daily functioning.

Studies report how symptoms evolved in the observed populations over defined time intervals, typically less than one week. When applied in studies examining patient-reported experiences of using Thiocolchicoside alongside common pain relievers, research describes the measurement of function and discomfort compared to using the pain reliever alone.

Research Gaps and Remaining Uncertainties

The research base is limited by older trials that had modest sample sizes and had variations in their design and reporting. The overall certainty remains low for the evidence base when Thiocolchicoside was studied as a standalone treatment. Follow-up durations were limited to the acute phase of symptoms, and there is limited information for long-term outcomes.

Data for certain groups remain insufficient. Research has not thoroughly evaluated outcomes for children and adolescents under 16 years of age, or in large, dedicated studies on older adults (over 65 years). Comparative evidence is lacking in several areas, and the existing studies provide context but not individual predictions, meaning the research does not determine how symptoms will change for any specific person.

Key Studies & References

  1. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature
  2. A multi-center, double-blind, randomized parallel-group Phase IV study comparing the efficacy and safety of thiocolchicoside - Turkish Journal of Physical Medicine and Rehabilitation

Frequently Asked Questions (FAQ)

Common questions about Thiospa (FAQ)


Q: What is Thiospa used for besides its main treatment area?

Regulatory documents define the primary purpose of Thiospa as an add-on treatment for painful muscular contractions associated with acute conditions, typically affecting the spinal column. The official labeling focuses on its use for painful muscular contractions and does not specify other therapeutic uses.


Q: How quickly can I expect Thiospa to start working?

Pharmacokinetic studies indicate that the main active substance of Thiospa reaches its highest concentration in the bloodstream (maximum plasma concentration) approximately one hour after taking an oral dose. This time frame indicates when the main active substance is typically detected at its highest level in the bloodstream.


Q: Does Thiospa have any long-term side effects that I should know about?

Official regulatory documents emphasize that this medicine is strictly restricted to short-term use only. Due to a potential safety risk from one of its metabolites (M2) that can damage cells, Thiospa should not be used for extended or long-term treatment.


Q: Are there any common over-the-counter (OTC) supplements that should be avoided while taking Thiospa?

Official product information requires caution with all Central Nervous System (CNS) active medicines, which may include some over-the-counter sleep aids or strong supplements. It is important to inform your prescriber about all concurrent substances, including supplements, to prevent potential interactions.


Q: Can older adults safely use Thiospa?

The medicine is approved for adults, meaning patients 16 years and older. Official information suggests careful supervision for elderly patients due to potential differences in how the body processes the medication.


Q: How is Thiospa different from a [general class of drugs, e.g., pain reliever]?

Thiospa's active ingredient, Thiocolchicoside, is officially classified as a centrally acting skeletal muscle relaxant and works primarily on the nervous system to ease muscle stiffness. This function is distinct from that of many common pain relievers (analgesics), which mainly work to block pain signals without directly relaxing the muscle structure.


Q: Can Thiospa affect my mood or cause anxiety?

Commonly reported side effects include general Central Nervous System (CNS) effects such as drowsiness, sleepiness, and dizziness. Official product information typically lists effects on the Central Nervous System as drowsiness and dizziness, but does not usually include mood changes or anxiety among the most frequent adverse reactions.


Q: Can I take Thiospa if I have kidney problems?

The drug's active substance is primarily removed from the body by the kidneys. Caution and dosage adjustment are necessary for patients who have severe kidney impairment to minimize the risk of increased side effects. Consultation with a prescribing professional regarding kidney health is required before use.


Q: Does Thiospa interact negatively with alcohol?

Official warnings advise against the concurrent consumption of alcohol, as it may enhance the drug’s Central Nervous System (CNS) depressant effects, increasing the risk of excessive drowsiness and impaired motor skills.


Q: What should I do if the side effects of Thiospa are mild but annoying?

Regulatory guidance suggests that if side effects such as nausea, diarrhea, or drowsiness persist or begin to worsen, you should consult your doctor or pharmacist. Patients are advised not to discontinue the medication or change the amount they are taking without consulting a healthcare professional.


Q: Does the time of day I take Thiospa matter?

The official dosing schedule requires that you take the medicine in a twice-daily frequency (e.g., every 12 hours) to ensure consistent levels and adherence to the daily dose limit. The specific time the dose cycle begins may be determined based on patient convenience, provided the required 12-hour interval is maintained.


Q: What are the key differences between the available strengths of Thiospa (if applicable)?

The oral form typically comes in 4 mg or 8 mg tablets/capsules. The key difference is the resulting maximum daily dose, which is 16 mg/day for the oral route (two 8 mg doses) and 8 mg/day for the IM injection route (two 4 mg doses).


Q: What is the risk of dependence or addiction with Thiospa?

Regulatory-based summaries indicate that Thiocolchicoside is not known to have any addiction potential or risk of physical dependence. Due to its use being limited to short-term treatment only, the potential for dependence or addiction is not a prominent concern mentioned in the official regulatory documents.


Q: What is the purpose of the long list of side effects in the official patient leaflet?

Regulatory guidance requires pharmaceutical companies to list all observed adverse events from clinical trials and post-marketing surveillance. This ensures patients and prescribers are fully informed of all potential adverse events, including those with low occurrence or an uncertain link to the medication.


Q: Can Thiospa interact with herbal remedies like St. John's Wort?

Official information requires patients to notify their healthcare professional about all medications and products, including herbal remedies and non-prescription drugs. This is a general safety measure to manage potential, though often undocumented, interactions.


Q: Do I need to change my diet while taking Thiospa?

The official label states that oral forms may be taken with or after food to help avoid stomach upset. No specific dietary restrictions are mandated by the regulatory label.


Q: What makes Thiospa unsuitable for people with certain heart conditions?

Official information advises caution for patients with pre-existing heart issues, such as hypertension or left ventricular dysfunction. This is due to the potential for generalized effects on smooth muscles. It is not an absolute contraindication, but the official label advises careful supervision when used by patients with these conditions.


Q: Is there a rebound effect or withdrawal when stopping Thiospa?

Due to the medicine's strict restriction to short-term use (maximum of 7 days), the risk of dependence and subsequent withdrawal effects is generally considered low. Patients should consult their doctor before abruptly stopping the medication, even after a short course of use.


Q: Can Thiospa be split or crushed, or must it be swallowed whole?

Regulatory-based patient advice directs that the oral form must be swallowed whole and should not be crushed or chewed, to maintain the product's defined release profile and ensure the intended therapeutic effect.


Q: Are there any lab tests required before or during treatment with Thiospa?

Routine, universally mandated tests are not specified for all patients. However, some regulatory guidance suggests that monitoring of renal (kidney) or hepatic (liver) function may be considered for individuals with pre-existing impairment, as these organs process and eliminate the medicine.


Q: How does Thiospa affect my liver function?

Thiospa is metabolized in the liver, and caution is formally advised for patients with moderate to severe liver impairment. It is important to notify your doctor immediately if you observe any signs of liver issues, such as yellowing of the skin or eyes.


Q: Is Thiospa safe to take with other prescription pain medications?

The official label notes that co-administration with other skeletal muscle relaxants is not recommended due to an additive effect. Additionally, caution is needed when combining it with NSAIDs or Paracetamol, as there are reports linking this specific combination to serious liver issues.


Q: How long does it take for Thiospa to leave my system?

Pharmacokinetic data from regulatory documents indicates that the time required for the active substance to be substantially eliminated from the body is approximately 13.5 to 14 hours after the final dose is administered.


Q: Does Thiospa make you more sensitive to the sun?

Some regulatory-based adverse reaction lists include photosensitivity (increased sensitivity to sunlight) as a possible, though uncommon, side effect. Patients are typically advised to use sun protection measures during treatment.


Q: What should I tell my dentist about taking Thiospa?

You should inform your dentist about taking Thiospa due to the potential for side effects like drowsiness and dizziness. This is important because the drug could interact with other sedating agents or anesthesia that may be used during dental procedures.


Q: Can Thiospa cause problems with my sleep pattern?

A common adverse effect listed in official documents is drowsiness or sleepiness. While this is not always a formal sleep pattern disorder like insomnia, the sedative properties of the medicine can potentially alter your normal sleep-wake cycle.


Q: Can people with high blood pressure safely use Thiospa?

Caution is typically advised for patients with conditions like hypertension (high blood pressure). Monitoring of blood pressure may be suggested by a healthcare professional, depending on the individual's history and the specific product formulation.


Q: Does Thiospa have any drug-drug interactions that are considered severe?

The most serious known risk is the association of severe cases of cytolytic or cholestatic hepatitis (a type of liver injury) when Thiospa is combined with NSAIDs or Paracetamol. This potential for severe outcome requires heightened caution.


Q: If Thiospa is stopped, how long until the effects completely wear off?

Based on the elimination rate described in pharmacokinetic studies, the drug's effects and substance are typically cleared from the body approximately 13.5 to 14 hours after the last dose.

How should Thiospa be stored and disposed of?

Official Storage and Disposal Profile (Regulatory Status)

The substance Tioclomarol (sometimes referred to as Thiospa) is not typically regulated as a human prescription or over-the-counter medicine by major governmental health agencies, such as the U.S. FDA, European EMA, or Health Canada. It is primarily classified as an anticoagulant rodenticide and a chemical compound.

Consequently, an official Summary of Product Characteristics (SmPC) or Prescribing Information containing specific, patient-facing storage, handling, and disposal instructions for pharmaceutical use is absent from authoritative drug regulatory databases.

Requirement Regulatory Status
Labeled Storage Conditions Not documented for human pharmaceutical use.
Child-Safety Requirements Not documented for human pharmaceutical use.
Disposal Instructions Governed by environmental/hazardous waste regulations, not standard drug formularies.

Any official regulatory requirements regarding the handling and disposition of Tioclomarol are typically found under environmental safety and industrial hazardous waste management protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thiospa found in:

A-Z Index: